Anticoagulants and Bleeding Disorders, Atrial Fibrillation
Conditions
Brief summary
All patients with atrial fibrillation who are treated with vitamin-k antagonists (warfarin, phenprocoumon) or non vitamin K oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in real world settings will be recorded in this register. Within this register a characterization of patients and therapy (with regard to medication, dose and duration) will be done. On basis of defined clinical relevant end points the long-term efficacy and safety will be evaluated.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients with atrial fibrillation * Indication for oral anticoagulant treatment
Exclusion criteria
* Missing Informed Consent Form * Missing Contact Informations for Follow up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thromboembolic Events | 1 year |
| Bleeding Events | 1 year |
Countries
Italy